Introduction

Short introduction to the topics of the volume Objects of Memory, Memory of Objects

Collection of Listeria monocytogenes Isolates from Milk, Dairy Products and Food Processing Environments in Slovakia for the Purposes of European Molecular Database

The molecular typing of Listeria monocytogenes isolates is an important tool for monitoring the spread of the strains in food chains, providing evidence for epidemiological investigations and for the detection of out-breaks. The demand of European typing data centralization, collection and sharing stimulated the generation of “EURL L. monocytogenes Database (EURL Lm DB)” in 2012 led by the European Union Reference Laboratory (EURL) for L. monocytogenes (ANSES Maisons-Alfort Laboratory for Food Safety, France) in close collaboration with Applied Maths. This database includes the typing results and epidemiological information on strains isolated from food, environmental or animal samples and it is in connection with human strains database TESSy (The European Surveillance System) led by the ECDC (European Centre for Disease Prevention and Control). In total 147 L. monocytogenes isolates were examined by PFGE (pulsed field gel electrophoresis) in 2014—2015 in VFI Dolny Kubin from different sources. Nearly half (68) of the 147 isolates in the national Slovak database came from milk or dairy products samples and the related manufacturing environment. In this work, 68 isolates associated with milk were selected and divided into 27 clusters (95 % similarity level) after combined comparison analysis (AscI and ApaI) by BioNumerics 6.6 software. Eight clusters included three or more similar PFGE profiles

DISTRIBUTION OF THE INVASIVE SPINY-CHEEK CRAYFISH (ORCONECTES LIMOSUS) IN THE CZECH REPUBLIC. PAST AND PRESENT

The American spiny-cheek crayfish, Orconectes limosus, was first introduced into European waters in 1890. The first literature record about the occurrence of O. limosus on the territory of the Czech Republic was published almost 100 years later – in 1989. The presence of this species in Czechia, however, was first recorded already in the 1960s, when crayfish were observed in the dead arms and pools adjacent to the river Elbe (Labe) in Central Bohemia. In the following few decades the spiny-cheek crayfish has spread into several larger rivers of the Elbe watershed and some of their smaller tributaries. The eastern part of the country (mostly belonging to the watershed of the river Morava) has not yet been colonised by this species. O. limosus can be found in lower reaches of a number of watercourses of a low stream order, but does not seem to penetrate far upstream in such localities. Its distribution in standing waters is largely the result of intentional humanmediated translocations. The long-term coexistence of Orconectes and native crayfish species has not yet been recorded, although both introduced and native crayfish at least occasionally come into contact. As O. limosus is a major carrier of the crayfish plague on the Czech territory, and crayfish plague outbreaks have been recently recorded, the dynamics of Orconectes invasion deserves careful monitoring in the future

Evolocumab and clinical outcomes in patients with cardiovascular disease

peer reviewedBACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years. RESULTS At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P<0.001). Relative to placebo, evolocumab treatment significantly reduced the risk of the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%]; hazard ratio, 0.85; 95% confidence interval [CI], 0.79 to 0.92; P<0.001) and the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.80; 95% CI, 0.73 to 0.88; P<0.001). The results were consistent across key subgroups, including the subgroup of patients in the lowest quartile for baseline LDL cholesterol levels (median, 74 mg per deciliter [1.9 mmol per liter]). There was no significant difference between the study groups with regard to adverse events (including new-onset diabetes and neurocognitive events), with the exception of injection-site reactions, which were more common with evolocumab (2.1% vs. 1.6%). CONCLUSIONS In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. These findings show that patients with atherosclerotic cardiovascular disease benefit from lowering of LDL cholesterol levels below current targets. © 2017 Massachusetts Medical Society